Children's Mercy, Kansas City, Missouri.
Aimmune Therapeutics, a Nestlé Health Science Company, Brisbane, California.
Ann Allergy Asthma Immunol. 2023 May;130(5):649-656.e4. doi: 10.1016/j.anai.2023.01.027. Epub 2023 Feb 2.
Peanut (Arachis hypogaea) allergen powder-dnfp (PTAH) is the first oral immunotherapy indicated for children aged 4 to 17 years with peanut allergy. There are limited real-world data on patients treated with PTAH.
To characterize pediatric patients treated with PTAH and associated treatment patterns in US clinical practice.
US-based physicians with allergy and immunology training treating patients with peanut allergy aged 4 to 17 years with PTAH were recruited from an existing physician panel and completed an online case report form (October to December 2021) with data abstracted from patient medical charts. Physician practice circumstances, patient characteristics, and PTAH treatment patterns were reported. Time to reach the 300-mg dose and treatment persistence were assessed using Kaplan-Meier analysis.
A geographically balanced sample of 43 physicians contributed data for 118 demographically diverse pediatric patients. Patients had heterogeneous diagnostic test results, with a wide range of peanut-specific immunoglobulin E levels; 6.8% received an oral food challenge. During the updosing phase, there were no temporary interruptions and 5.1% of the patients required downdosing. Patients reached the 300-mg dose at a median of 21.3 weeks post-initiation. The rate of PTAH persistence at 24 weeks was 93.4%. Only 1 patient discontinued treatment because of treatment-related systemic allergic symptoms, and the remaining discontinuations were for reasons other than treatment-related symptoms. Prophylactic antihistamines were used by 33.9% of the patients to prevent PTAH adverse effects.
PTAH was prescribed in demographically diverse patients with a wide range of peanut-specific immunoglobulin E levels. Treatment persistence with PTAH was high in this study population, with a small number of patients experiencing treatment modification.
花生（Arachis hypogaea）过敏原粉-dnfp（PTAH）是第一种针对 4 至 17 岁花生过敏儿童的口服免疫疗法。目前，关于接受 PTAH 治疗的患者的真实世界数据有限。
描述美国临床实践中接受 PTAH 治疗的儿科患者的特征和相关治疗模式。
从现有的医生小组中招募了具有过敏和免疫学培训背景、治疗 4 至 17 岁花生过敏患者的美国医生，并使用从患者病历中提取的数据填写了在线病例报告表（2021 年 10 月至 12 月）。报告了医生的实践情况、患者特征和 PTAH 治疗模式。使用 Kaplan-Meier 分析评估达到 300mg 剂量的时间和治疗持续时间。
43 名地理位置分布均衡的医生提供了 118 名具有不同人口统计学特征的儿科患者的数据。患者的诊断性检测结果存在差异，花生特异性免疫球蛋白 E 水平范围广泛；6.8%的患者接受了口服食物挑战。在加量阶段，没有临时中断，5.1%的患者需要减剂量。患者从开始治疗到达到 300mg 剂量的中位数时间为 21.3 周。在 24 周时，PTAH 持续治疗率为 93.4%。只有 1 名患者因治疗相关的全身性过敏症状而停止治疗，其余的停药原因与治疗相关症状无关。为预防 PTAH 不良反应，33.9%的患者使用了预防性抗组胺药。
在具有广泛花生特异性免疫球蛋白 E 水平的患者中，开具了 PTAH 处方。在本研究人群中，PTAH 的治疗持续率较高，只有少数患者需要进行治疗调整。
